<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01835054</url>
  </required_header>
  <id_info>
    <org_study_id>MOP#102737</org_study_id>
    <nct_id>NCT01835054</nct_id>
  </id_info>
  <brief_title>Determinants of the Progression and Outcome of Mitral Regurgitation</brief_title>
  <acronym>PROGRAM</acronym>
  <official_title>Determinants of the Progression and Outcome of Mitral Regurgitation-PROGRAM STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart and Stroke Foundation of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitral regurgitation (MR) is one of the most frequent valve lesions, both in North America
      and in Europe, and its prevalence is increasing with the aging of the population. Organic
      Mitral Regurgitation (OMR) and Ischemic Mitral Regurgitation are the 2 main categories of MR.
      Organic or primary MR is caused by an anatomic alteration of the valvular or subvalvular
      mitral apparatus and refers to rheumatic MR and degenerative MR that includes mitral leaflet
      prolapse and flail leaflet. In the past 20 years, degenerative MR has become, by far, the
      most frequent cause of severe MR leading to surgery in the western world. However, the best
      current treatment for OMR remains uncertain and controversial. We have obtained preliminary
      data showing that OMR is a dynamic lesion. Hence, the echocardiographic evaluation of MR at
      rest, as generally performed during routine clinical exam, does not necessarily reflect the
      status of MR during patient's daily activities and thereby does not adequately assess the
      risk of rapid progression and poor outcome in these patients. The objective of this study is
      to identify the independent predictors of disease progression and outcome in patients with
      asymptomatic chronic OMR and to develop and validate novel imaging and circulating biomarkers
      to improve risk stratification and therapeutic decision-making process in patients with
      chronic asymptomatic primary OMR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mitral regurgitation (MR) is one of the most frequent valve lesions, both in North America
      and in Europe, and its prevalence is increasing owing to the aging of the population. There
      are 2 main categories of MR: Organic Mitral Regurgitation (OMR) and Ischemic Mitral
      Regurgitation. Organic or primary MR is caused by an anatomic alteration of the valvular or
      subvalvular mitral apparatus and refers to rheumatic MR and degenerative MR that includes
      mitral leaflet prolapse and flail leaflet. In the past 20 years, degenerative MR has become,
      by far, the most frequent cause of severe MR leading to surgery in the western world.
      However, the best current treatment for OMR remains uncertain and controversial. This is, in
      large part, due to the lack of prospective data on the determinants of OMR progression and
      outcome. Furthermore, we have obtained preliminary data showing that OMR is a dynamic lesion.
      Hence, the echocardiographic evaluation of MR at rest, as generally performed during routine
      clinical exam, does not necessarily reflect the status of MR during patient's daily
      activities and thereby does not adequately assess the risk of rapid progression and poor
      outcome in these patients.

      The general objective of this study is thus: to identify the independent predictors of
      disease progression and outcome in patients with asymptomatic chronic OMR and to develop and
      validate novel imaging and circulating biomarkers to improve risk stratification and
      therapeutic decision-making process in patients with chronic asymptomatic primary OMR.

      The specific aims of the study are: (1) To obtain and analyze: a) the dynamic changes in MR
      severity, pulmonary arterial pressure, and LV function during exercise; b) the maximum
      exercise capacity; c) the metabolic profile; d) the plasma natriuretic peptides, e) the
      degree and localization of myocardial fibrosis measured by cardiac magnetic resonance Imaging
      (MRI); f) the blood markers of myocardial extracellular matrix (ECM) turnover; g) the
      progression of MR severity and LV dysfunction during follow-up; and h) the occurrence of
      adverse clinical outcomes (i.e. symptoms, LV dysfunction, atrial fibrillation (Holter ECG),
      pulmonary hypertension, heart failure, cardiovascular death) during follow-up in a series of
      440 patients with at least moderate OMR and no symptoms at baseline. (2) To analyze the valve
      tissue samples explanted from the patients who will undergo mitral valve repair with
      quadrangular resection during follow-up in order to document the presence of lipids,
      inflammation, and expression of metalloproteinases (MMPs). (3) To obtain and analyze the
      postoperative changes in LV geometry and function, pulmonary arterial pressure, symptoms, and
      exercise capacity in the subset of patients who will undergo mitral valve surgery during
      follow-up. (4) To evaluate the usefulness of the exercise induced changes in MR severity,
      pulmonary arterial pressure, and LV function (i.e. contractile reserve), and of the blood
      levels of natriuretic peptides and ECM biomarkers for the prediction of rapid progression to
      LV dysfunction and adverse events. (5) To examine the relationship between the metabolic
      abnormalities linked to visceral obesity and the progression and outcome of OMR. (6) To
      determine, among the baseline clinical, echocardiographic, MRI, metabolic, and biomarkers
      variables, those which are independently associated with the progression of MR severity and
      LV dysfunction, and the occurrence of adverse clinical outcomes in patients with OMR.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Combined clinical and echocardiographic endpoint</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>The primary outcome is the time to occurrence of the first composite end-point: development of symptoms, left ventricular (LV) dysfunction (LV Ejection Fraction&lt;60% and/or LV end diastolic diameter &gt;40mm), ventricular arrhytmia requiring hospitalization, mediaction and/or implantation of defibrillator, atrial fibrillation or flutter, pulmonary arterial hypertension (resting systolic pressure &gt;50mmHg), occurence of pulmonary oedema, congestive heart failure or cardiovascular death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression of MR severity</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>The annualized progression rate of MR severity will be calculated as the difference between effective regurgitant orifice, regurgitant volume, and vena contracta width measured at baseline and those measured at the last follow-up divided by the time between the first and last examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of pulmonary arterial hypertension</measure>
    <time_frame>Patients will be folowed for 4 years</time_frame>
    <description>The annualized progression rate of resting systolic pulmonary arterial pressure will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of LV dysfuntion prior to surgery</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>The annualized progression rate of LVEF, LV end-systolic dimension, and LV myocardial global peak systolic velocities and global longitudinal strain will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum exercise capacity at baselin and following mitral valve surgery</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>Maximum exercise capacity at baseline as measured by the percentage of age and gender predicted VO2max. We will determine which are, among the clinical and Doppler-echocardiographic variables, the independent determinants of maximum exercise capacity at baseline. The baseline exercise capacity will also be used as an independent variable, i.e. we will determine if it is an independent predictor of the primary end-point and of the other secondary end-points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite end-point prior to mitral valve surgery</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>i.e. follow-up censored at surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite primary end-point after mitral vale surgery</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>i.e. time zero set at surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral valve surgery</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>Motivated by the occurrence of symptoms, LV systolic dysfunction, atrial fibrillation, and/or resting pulmonary pressure &gt; 50 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arrhythmic burden</measure>
    <time_frame>Patients will be followed for 4 years</time_frame>
    <description>Number and percentage of ventricular ectopic per 24 h, percent time in atrial fibrillation, or flutter per 24 h.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
    <description>At study entry, patients have 1) a clinical assessment including metabolic risk profile; 2) a blood sample for analysis of metabolic, cardiac neurohormonal blood biomarkers and DNA collection; 3) a complete rest doppler echocardiography; 4) an exercise stress doppler echocardiography; 5) a cardiopulmonary exercise testing; 6) a magnetic resonance Imaging (MRI); 7) a 24-hour Holter ECG.
At follow-up, patients have 1) a clinical events assessment; 2) a blood sample analysis; 3) a resting echocardiography every year; 4) MRI (at preop. evaluation in the subset of patients undergoing surgery); 5) a 24-hour Holter ECG (at 2-year and postop.).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood biomarkers</intervention_name>
    <description>Observational Study using Imaging and Biomarkers</description>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA collection</intervention_name>
    <description>Observational Study using Imaging and Biomarkers</description>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Observational Study using Imaging and Biomarkers</description>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiopulmonary exercise testing</intervention_name>
    <description>Observational Study using Imaging and Biomarkers</description>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Magnetic resonance imaging (MRI)</intervention_name>
    <description>Observational Study using Imaging and Biomarkers</description>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise stress doppler echocardiography</intervention_name>
    <description>Observational Study using Imaging and Biomarkers</description>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Holter ECG</intervention_name>
    <description>Observational Study using Imaging and Biomarkers</description>
    <arm_group_label>Patients with mitral regurgitation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fasting blood sample (serum, lithium-heparin, EDTA) and white cells - Tissue (explanted
      mitral valves)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort will be selected at primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 or 21 years (Legal age according to the countries involved in this study)

          -  Presence of at least moderate chronic OMR defined as an ERO ≥20mm2 and/or a
             regurgitant volume ≥30mL

        Exclusion Criteria:

          -  MR due to ischemic heart disease or cardiomyopathy

          -  &gt; mild mitral stenosis, aortic regurgitation, aortic stenosis or pulmonary stenosis

          -  previous valve operation

          -  history of myocardial infarction or angiographycally documented coronary stenosis

          -  congenital or pericardial heart disease

          -  endocarditis

          -  contra-indication or inability to exercise

          -  pregnancy

          -  Class I or II indication for mitral valve operation according to the 2006-2007
             ACC/AHA/ESC guidelines

          -  Typical contraindications to contrast-enhanced MRI (surgery in the last 3 months,
             defibrillator, pericardial electrodes, brain surgery, aneurysm clipping,
             neurostimulator, electric stimulation device or magnetically activated, cochlear
             implant, insulin pump or medication delivery device, Swan-Ganz catheter)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Pibarot, PhD, DVM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Universitaire de Cardiologie et de Pneumologie de Québec</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe Pibarot, PhD, DVM</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>5938</phone_ext>
    <email>Philippe.Pibarot@med.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haifa Mahjoub, MD, PhDs</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>2647</phone_ext>
    <email>haifa.mahjoub@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizio Lancellotti, MD, PhD</last_name>
      <phone>32(0)4/366 7194</phone>
      <email>plancellotti@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Patrizio Lancellotti, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Magne, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Pibarot, PhD, DVM</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>5938</phone_ext>
      <email>Philippe.Pibarot@med.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Oumhani Toubal, MD, Fellow</last_name>
      <phone>418-656-5711</phone>
      <phone_ext>2647</phone_ext>
      <email>oumhani.toubal@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Pibarot, PhD, DVM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital (CHU) of Brest, Hôpital La Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florent Le Ven, MD</last_name>
      <phone>33298347391</phone>
      <email>florent.leven@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Florent Le Ven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Magne J, Mahjoub H, Pibarot P, Pirlet C, Pierard LA, Lancellotti P. Prognostic importance of exercise brain natriuretic peptide in asymptomatic degenerative mitral regurgitation. Eur J Heart Fail. 2012 Nov;14(11):1293-302. doi: 10.1093/eurjhf/hfs114. Epub 2012 Jul 10.</citation>
    <PMID>22782970</PMID>
  </reference>
  <reference>
    <citation>Magne J, Mahjoub H, Pierard LA, O'Connor K, Pirlet C, Pibarot P, Lancellotti P. Prognostic importance of brain natriuretic peptide and left ventricular longitudinal function in asymptomatic degenerative mitral regurgitation. Heart. 2012 Apr;98(7):584-91. doi: 10.1136/heartjnl-2011-301128. Epub 2012 Feb 18.</citation>
    <PMID>22342982</PMID>
  </reference>
  <reference>
    <citation>Lancellotti P, Magne J. Stress testing for the evaluation of patients with mitral regurgitation. Curr Opin Cardiol. 2012 Sep;27(5):492-8. doi: 10.1097/HCO.0b013e3283565c3b. Review.</citation>
    <PMID>22872130</PMID>
  </reference>
  <reference>
    <citation>Sénéchal M, Michaud N, Machaalany J, Bernier M, Dubois M, Magne J, Couture C, Mathieu P, Bertrand OF, Voisine P. Relation of mitral valve morphology and motion to mitral regurgitation severity in patients with mitral valve prolapse. Cardiovasc Ultrasound. 2012 Jan 27;10:3. doi: 10.1186/1476-7120-10-3.</citation>
    <PMID>22284298</PMID>
  </reference>
  <reference>
    <citation>Van de Heyning CM, Magne J, Vrints CJ, Piérard L, Lancellotti P. The role of multi-imaging modality in primary mitral regurgitation. Eur Heart J Cardiovasc Imaging. 2012 Feb;13(2):139-51. doi: 10.1093/ejechocard/jer257. Epub 2011 Nov 29. Review.</citation>
    <PMID>22127625</PMID>
  </reference>
  <reference>
    <citation>Magne J, Lancellotti P, O'Connor K, Van de Heyning CM, Szymanski C, Piérard LA. Prediction of exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. J Am Soc Echocardiogr. 2011 Sep;24(9):1004-12. doi: 10.1016/j.echo.2011.04.003. Epub 2011 May 17.</citation>
    <PMID>21592726</PMID>
  </reference>
  <reference>
    <citation>Magne J, Lancellotti P, Piérard LA. Exercise-induced changes in degenerative mitral regurgitation. J Am Coll Cardiol. 2010 Jul 20;56(4):300-9. doi: 10.1016/j.jacc.2009.12.073.</citation>
    <PMID>20633822</PMID>
  </reference>
  <reference>
    <citation>Magne J, Lancellotti P, Piérard LA. Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation. Circulation. 2010 Jul 6;122(1):33-41. doi: 10.1161/CIRCULATIONAHA.110.938241. Epub 2010 Jun 21.</citation>
    <PMID>20566950</PMID>
  </reference>
  <reference>
    <citation>Magne J, Mathieu P, Dumesnil JG, Tanné D, Dagenais F, Doyle D, Pibarot P. Impact of prosthesis-patient mismatch on survival after mitral valve replacement. Circulation. 2007 Mar 20;115(11):1417-25. Epub 2007 Mar 5.</citation>
    <PMID>17339554</PMID>
  </reference>
  <reference>
    <citation>Mascle S, Schnell F, Thebault C, Corbineau H, Laurent M, Hamonic S, Veillard D, Mabo P, Leguerrier A, Donal E. Predictive value of global longitudinal strain in a surgical population of organic mitral regurgitation. J Am Soc Echocardiogr. 2012 Jul;25(7):766-72. doi: 10.1016/j.echo.2012.04.009. Epub 2012 May 19.</citation>
    <PMID>22609096</PMID>
  </reference>
  <reference>
    <citation>Donal E, Mascle S, Brunet A, Thebault C, Corbineau H, Laurent M, Leguerrier A, Mabo P. Prediction of left ventricular ejection fraction 6 months after surgical correction of organic mitral regurgitation: the value of exercise echocardiography and deformation imaging. Eur Heart J Cardiovasc Imaging. 2012 Nov;13(11):922-30. doi: 10.1093/ehjci/jes068. Epub 2012 Apr 14.</citation>
    <PMID>22504944</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2013</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>Philippe Pibarot</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Mitral regurgitation</keyword>
  <keyword>Mitral valve prolapse</keyword>
  <keyword>Echocardiography, Doppler</keyword>
  <keyword>Stress echocardiography</keyword>
  <keyword>Cardiopulmonary exercice testing</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Cardiac neurohormones</keyword>
  <keyword>Visceral obesity</keyword>
  <keyword>Cardiometabolic risk</keyword>
  <keyword>Risk stratification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

